Navigation Links
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Date:5/26/2009

r repeated acute episodes. Despite currently available therapies, readmission rates for heart failure patients over the age of 65 are as high as 42 percent within one year of hospital discharge. Mortality rates over the five-year period following a diagnosis of heart failure are approximately 60 percent. The high morbidity and mortality in the setting of current therapies points to the need for novel therapeutics that offer further reductions in morbidity and mortality. The annual cost of heart failure to the U.S. health care system is estimated to be $35 billion dollars. A portion of that cost is attributable to drugs used to treat each of chronic and acute heart failure. Sales of drugs to treat chronic heart failure reached almost $2.5 billion in 2006 while sales of drugs to treat acute heart failure reached over $350 million in 2007.

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company's drug candidates and poten
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... 2011 During a ,Day of Science, more than 30 ... what it was like to be scientists for a day ... Inc. (S2S). The "A Day in the Life of a ... programs offered by S2S that seeks to address the fact ...
... (Nasdaq: DNDN ) today announced that management will present ... in New York City, NY on May 25, 2011 at 1:00 ... Palos Verdes, CA on June 7, 2011 at 2:00 p.m. PT ... available for replay from Dendreon,s website, www.dendreon.com .  If you ...
... BRISBANE, Calif., May 19, 2011 InterMune, Inc. (NASDAQ: ... of its 2011 Analyst Day presentations on Thursday, May ... in New York.  Presentations by InterMune,s executive management team ... and a comprehensive update of InterMune,s commercial and scientific ...
Cached Biology Technology:Local Partnership Addresses Lagging Scores and Interest in Science and Math Among Students 2Local Partnership Addresses Lagging Scores and Interest in Science and Math Among Students 3InterMune to Webcast 2011 Analyst Day Presentations 2
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
(Date:10/15/2014)... Gauß-Allianz has admitted Johannes Gutenberg University Mainz (JGU) ... science hub continues to maintain a significant nationwide ... , "The acceptance of Johannes Gutenberg University Mainz ... a milestone in the national and international competition ... state of Rhineland-Palatinate can be proud that Mainz ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... differences seen among patients with schizophrenia may be explained by ... risk genes. These findings appear in a new imaging-genetics study ... The study revealed that people with schizophrenia who had ... to develop the illness at a younger age and had ...
... like a bomb shelter, Perry Gerakines makes something ordinary yet truly ... No, this ice needs such intense cold and low pressure to ... Earth. And when Gerakines makes the ice, he must keep the ... pollen. These ultrathin layers turn out to be perfect for ...
... cells during puberty to help navigate the complex social world ... current issue of the Proceedings of the National Academy ... cells you,re born with are all you get. After studies ... wisdom held that such growth was limited to two brain ...
Cached Biology News:Single gene might explain dramatic differences among people with schizophrenia 2NASA Goddard lab works at extreme edge of cosmic ice 2NASA Goddard lab works at extreme edge of cosmic ice 3NASA Goddard lab works at extreme edge of cosmic ice 4Brain adds cells in puberty to navigate adult world 2
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... and Protein G bind specifically to Fc ... and Protein G conjugates are commonly used ... and immunoglobulin subtypes from serum, hybridoma ascites ... fluids. These reagents are also commonly used ...
... dishes with stacking feature for easy storage. Linkage: ... created to easily match Cornings product number. If ... old Sigma-Aldrich number (Z70,947-6) or contact customer service ... Comp Dim: surface area 55 cm 2 ...
... thermal cycler blocks, 96-well PCR plate, 0.3ml maximum ... seals), Cut-away corner , Fits all 0.2ml thermal ... capillary sequencers, Clear well bottom for sample visibility, ... Films and Foils, Heat Seals and Flat and ...
Biology Products: